Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix(PSCC).Methods In this study, 4 patients with histologi...Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix(PSCC).Methods In this study, 4 patients with histologically confirmed papillary serous carcinoma of the uterine cervix were retrospectively investigated. Pap smears, human papillomavirus(HPV) screening, tumor marker status, biopsy analysis, and relevant imaging examinations were conducted for the confirmation of primary diagnosis and recurrence. Patients underwent surgery, chemotherapy, or radiotherapy, and survival were the main endpoint.Results The 4 patients were diagnosed with IB1, IB1, IIA, or IIIB disease. Two patients(2/4) presented with recurrence within 18 months after primary therapy. Compared with chemotherapy alone(progressionfree survival(PFS): 11 months), radiotherapy combined with adjuvant chemotherapy showed favorable PFS rates(PFS: 20, 36, 13 months in 3 cases), although valid statistical analysis was not feasible because of the small sample size. The 5-year survival rate was 0%, and the 3-year survival rate was 75%. Our data, in agreement with the literature evidence, showed that the number of moderate-risk and high-risk factors in patients diagnosed with PSCC at an early stage was higher than that in patients diagnosed with common adenocarcinoma/squamous carcinoma of the uterine cervix.Conclusion PSCC has a poor clinical prognosis, and compared with chemotherapy alone, radiotherapy combined with adjuvant chemotherapy may lead to improved PFS.展开更多
Uterine papillary serous carcinoma(UPSC) was established as a distinct type of endometrial carcinoma by Lauchlan in 1981 and Hendrickson et al in 1982, and ac- counted for 1 % - 10% of endometrial cancers. The occurre...Uterine papillary serous carcinoma(UPSC) was established as a distinct type of endometrial carcinoma by Lauchlan in 1981 and Hendrickson et al in 1982, and ac- counted for 1 % - 10% of endometrial cancers. The occurrencer of papillary patterns of en- dometrial adenocarcinoma had been reportedly recognized since 1900, while until the late 1970s several authors have had described a variant of papillary endometrial cancer. UPSC is a morphologically unique variant of endometrial carcinoma that is pathologically defined by the presence of high nuclear grade, distinct papillary architechtural changes, psammoma bodies, and extensive lymph - vascular space invasion. CA125 is often mentioned a useful tumor marker either for diagnosis before starting treatment or in monitoring recurrence. The optimal treatment of UPSC is controversial and appears to be dependent upon the stage of the disease. Primary surgery comprised of TAH/BSO and complete staging is the mainstay of treatment. The patients with recurrent UPSC in many studies were treated with various combinations of surgery , radiation therapy, and chemotherapy. The molecular basis for the gneeral poor response of UPSC to adjuvant chemotherapy and radiotherapy is not well under- stood. UPSC tumors are more often aneuploid and contain overexpressed mutant p53 protein as compared to endometrioid adenocarcinoma. Unlike patients with adenocarcinoma of the endometrium, women with UPSC were less likely to be obese, hypertensive, or diabetic.展开更多
宫颈大细胞神经内分泌癌(large cell neuroendocrine carcinoma,LCNEC)是一种具有内分泌功能的恶性肿瘤,是抗利尿激素分泌异常综合征(syndrome of inappropriate secretion of antidiuretic hormone,SIADH)的病因之一。报告1例妊娠合并...宫颈大细胞神经内分泌癌(large cell neuroendocrine carcinoma,LCNEC)是一种具有内分泌功能的恶性肿瘤,是抗利尿激素分泌异常综合征(syndrome of inappropriate secretion of antidiuretic hormone,SIADH)的病因之一。报告1例妊娠合并宫颈LCNEC患者,入院时存在轻度低钠血症,剖宫产终止妊娠后行化疗,化疗过程中出现了重度低钠血症伴抽搐、意识不清,诊断为SIADH。给予镇静镇痛、补钠、补钾、降颅压、纠正酸碱失衡等抢救措施后,患者血Na+水平恢复正常,随后行3个周期顺铂+依托泊苷方案化疗以及同步放化疗。最终患者肿瘤复发,因Ⅳ度骨髓抑制、体能状况差,无法耐受抗肿瘤治疗而终止治疗后死亡。SIADH早期识别与诊断困难,诊治不当可导致认知障碍、癫痫、昏迷和渗透性脱髓鞘综合征等,影响患者预后。展开更多
宫颈神经内分泌癌(neuroendocrine carcinoma of the cervix,NECC)是一种罕见的恶性程度极高的妇科肿瘤。临床上对NECC的组织来源、发病机制并不明确。NECC没有标准的治疗方案,多是结合宫颈鳞状细胞癌、腺癌和小细胞肺癌的治疗经验制定...宫颈神经内分泌癌(neuroendocrine carcinoma of the cervix,NECC)是一种罕见的恶性程度极高的妇科肿瘤。临床上对NECC的组织来源、发病机制并不明确。NECC没有标准的治疗方案,多是结合宫颈鳞状细胞癌、腺癌和小细胞肺癌的治疗经验制定治疗方案。近年来大样本队列基因组研究显示,NECC与宫颈外神经内分泌癌具有不同的基因组学特征,对NECC与宫颈外神经内分泌癌之间的生物学和治疗相关性提出了质疑。由于NECC的罕见性,获得足够数量的患者进行疗效试验的可能性很低,这阻碍了NECC标准治疗方案的制定。基因检测能为NECC靶向药物的个体化治疗提供策略。多项研究结果显示,NECC具有潜在的可调控的治疗靶点,免疫疗法与放射疗法结合可以延长晚期复发性NECC患者的长期生存。综述NECC的分子特征、靶向药物及免疫治疗的研究进展。展开更多
宫颈小细胞神经内分泌癌(small cell neuroendocrine carcinoma of the cervix,SCNCC)早期易发生淋巴转移,病理表现独特,易复发,预后差。报告1例SCNCCⅢC1r期病例资料,患者因间断性阴道出血伴下腹痛1个月余就诊,结合盆腔磁共振成像、全...宫颈小细胞神经内分泌癌(small cell neuroendocrine carcinoma of the cervix,SCNCC)早期易发生淋巴转移,病理表现独特,易复发,预后差。报告1例SCNCCⅢC1r期病例资料,患者因间断性阴道出血伴下腹痛1个月余就诊,结合盆腔磁共振成像、全腹CT及宫腔镜活检结果诊断为SCNCCⅢC1r期,根据2022年美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)指南,结合该患者病情,给予患者3个周期的卡铂+依托泊苷新辅助化疗,后行腹腔镜下广泛性子宫切除术+双侧卵巢切除术+双侧输卵管切除术+盆腔淋巴结清扫术+腹主动脉旁淋巴结切除术+抗肿瘤药物腹腔灌注治疗(奈达铂冲洗腹腔)+双侧输尿管支架植入术,术后继续化疗3个周期,术后随访13个月未见复发。展开更多
Junctional adhesion molecule-A(JAM-A),also known as the F11 receptor(F11R),is one of the tight junction components.JAM-A is a transmembrane glycoprotein that regulates many cellular processes,i.e.,angiogenesis,leukocy...Junctional adhesion molecule-A(JAM-A),also known as the F11 receptor(F11R),is one of the tight junction components.JAM-A is a transmembrane glycoprotein that regulates many cellular processes,i.e.,angiogenesis,leukocyte transendothelial migration,intercellular permeability,epithelial-to-mesenchymal transition,and platelet activation.Of note,it is involved in the pathogenesis of various cancer types,including gynecological cancers.Only a few studies are available about this cancer type.Observed aberrant JAM-A expression in gynecological cancers correlates with poor patient prognosis.To the best of our knowledge,conflicting JAM-A roles in various cancer types suggest that its involvement is complex and tumor-type specific.The underlying molecular mechanisms and pathways responsible for JAM-A functions were not fully elucidated and need to be identified.Finding appropriate novel molecular cancer biomarkers may reduce observed very high mortality rates and could contribute to personalized treatment development.The main aim of the present viewpoint article is to report the current knowledge about JAM-A participation in gynecological malignancies.展开更多
文摘Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix(PSCC).Methods In this study, 4 patients with histologically confirmed papillary serous carcinoma of the uterine cervix were retrospectively investigated. Pap smears, human papillomavirus(HPV) screening, tumor marker status, biopsy analysis, and relevant imaging examinations were conducted for the confirmation of primary diagnosis and recurrence. Patients underwent surgery, chemotherapy, or radiotherapy, and survival were the main endpoint.Results The 4 patients were diagnosed with IB1, IB1, IIA, or IIIB disease. Two patients(2/4) presented with recurrence within 18 months after primary therapy. Compared with chemotherapy alone(progressionfree survival(PFS): 11 months), radiotherapy combined with adjuvant chemotherapy showed favorable PFS rates(PFS: 20, 36, 13 months in 3 cases), although valid statistical analysis was not feasible because of the small sample size. The 5-year survival rate was 0%, and the 3-year survival rate was 75%. Our data, in agreement with the literature evidence, showed that the number of moderate-risk and high-risk factors in patients diagnosed with PSCC at an early stage was higher than that in patients diagnosed with common adenocarcinoma/squamous carcinoma of the uterine cervix.Conclusion PSCC has a poor clinical prognosis, and compared with chemotherapy alone, radiotherapy combined with adjuvant chemotherapy may lead to improved PFS.
文摘Uterine papillary serous carcinoma(UPSC) was established as a distinct type of endometrial carcinoma by Lauchlan in 1981 and Hendrickson et al in 1982, and ac- counted for 1 % - 10% of endometrial cancers. The occurrencer of papillary patterns of en- dometrial adenocarcinoma had been reportedly recognized since 1900, while until the late 1970s several authors have had described a variant of papillary endometrial cancer. UPSC is a morphologically unique variant of endometrial carcinoma that is pathologically defined by the presence of high nuclear grade, distinct papillary architechtural changes, psammoma bodies, and extensive lymph - vascular space invasion. CA125 is often mentioned a useful tumor marker either for diagnosis before starting treatment or in monitoring recurrence. The optimal treatment of UPSC is controversial and appears to be dependent upon the stage of the disease. Primary surgery comprised of TAH/BSO and complete staging is the mainstay of treatment. The patients with recurrent UPSC in many studies were treated with various combinations of surgery , radiation therapy, and chemotherapy. The molecular basis for the gneeral poor response of UPSC to adjuvant chemotherapy and radiotherapy is not well under- stood. UPSC tumors are more often aneuploid and contain overexpressed mutant p53 protein as compared to endometrioid adenocarcinoma. Unlike patients with adenocarcinoma of the endometrium, women with UPSC were less likely to be obese, hypertensive, or diabetic.
文摘宫颈大细胞神经内分泌癌(large cell neuroendocrine carcinoma,LCNEC)是一种具有内分泌功能的恶性肿瘤,是抗利尿激素分泌异常综合征(syndrome of inappropriate secretion of antidiuretic hormone,SIADH)的病因之一。报告1例妊娠合并宫颈LCNEC患者,入院时存在轻度低钠血症,剖宫产终止妊娠后行化疗,化疗过程中出现了重度低钠血症伴抽搐、意识不清,诊断为SIADH。给予镇静镇痛、补钠、补钾、降颅压、纠正酸碱失衡等抢救措施后,患者血Na+水平恢复正常,随后行3个周期顺铂+依托泊苷方案化疗以及同步放化疗。最终患者肿瘤复发,因Ⅳ度骨髓抑制、体能状况差,无法耐受抗肿瘤治疗而终止治疗后死亡。SIADH早期识别与诊断困难,诊治不当可导致认知障碍、癫痫、昏迷和渗透性脱髓鞘综合征等,影响患者预后。
文摘宫颈神经内分泌癌(neuroendocrine carcinoma of the cervix,NECC)是一种罕见的恶性程度极高的妇科肿瘤。临床上对NECC的组织来源、发病机制并不明确。NECC没有标准的治疗方案,多是结合宫颈鳞状细胞癌、腺癌和小细胞肺癌的治疗经验制定治疗方案。近年来大样本队列基因组研究显示,NECC与宫颈外神经内分泌癌具有不同的基因组学特征,对NECC与宫颈外神经内分泌癌之间的生物学和治疗相关性提出了质疑。由于NECC的罕见性,获得足够数量的患者进行疗效试验的可能性很低,这阻碍了NECC标准治疗方案的制定。基因检测能为NECC靶向药物的个体化治疗提供策略。多项研究结果显示,NECC具有潜在的可调控的治疗靶点,免疫疗法与放射疗法结合可以延长晚期复发性NECC患者的长期生存。综述NECC的分子特征、靶向药物及免疫治疗的研究进展。
文摘宫颈小细胞神经内分泌癌(small cell neuroendocrine carcinoma of the cervix,SCNCC)早期易发生淋巴转移,病理表现独特,易复发,预后差。报告1例SCNCCⅢC1r期病例资料,患者因间断性阴道出血伴下腹痛1个月余就诊,结合盆腔磁共振成像、全腹CT及宫腔镜活检结果诊断为SCNCCⅢC1r期,根据2022年美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)指南,结合该患者病情,给予患者3个周期的卡铂+依托泊苷新辅助化疗,后行腹腔镜下广泛性子宫切除术+双侧卵巢切除术+双侧输卵管切除术+盆腔淋巴结清扫术+腹主动脉旁淋巴结切除术+抗肿瘤药物腹腔灌注治疗(奈达铂冲洗腹腔)+双侧输尿管支架植入术,术后继续化疗3个周期,术后随访13个月未见复发。
文摘Junctional adhesion molecule-A(JAM-A),also known as the F11 receptor(F11R),is one of the tight junction components.JAM-A is a transmembrane glycoprotein that regulates many cellular processes,i.e.,angiogenesis,leukocyte transendothelial migration,intercellular permeability,epithelial-to-mesenchymal transition,and platelet activation.Of note,it is involved in the pathogenesis of various cancer types,including gynecological cancers.Only a few studies are available about this cancer type.Observed aberrant JAM-A expression in gynecological cancers correlates with poor patient prognosis.To the best of our knowledge,conflicting JAM-A roles in various cancer types suggest that its involvement is complex and tumor-type specific.The underlying molecular mechanisms and pathways responsible for JAM-A functions were not fully elucidated and need to be identified.Finding appropriate novel molecular cancer biomarkers may reduce observed very high mortality rates and could contribute to personalized treatment development.The main aim of the present viewpoint article is to report the current knowledge about JAM-A participation in gynecological malignancies.
